Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy

Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy

Abstract Background Renal medullary carcinoma (RMC) is a highly aggressive cancer in need of new therapeutic strategies. The neddylation pathway can protect cells from DNA damage induced by the platinum‐based chemotherapy used in RMC. We investigated if neddylation inhibition with pevonedistat will...

Full description

Bibliographic Details
Main Authors: Daniel D. Shapiro, Niki Millward Zacharias, Durga N. Tripathi, Menuka Karki, Jean‐Philippe Bertocchio, Melinda Soeung, Rong He, Mary E. Westerman, Jianjun Gao, Priya Rao, Truong N. A. Lam, Eric Jonasch, Luigi Perelli, Emily H. Cheng, Alessandro Carugo, Timothy P. Heffernan, Cheryl L. Walker, Giannicola Genovese, Nizar M. Tannir, Jose A. Karam, Pavlos Msaouel
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Clinical and Translational Medicine
Subjects:
chemotherapy
neddylation
pevonedistat
renal medullary carcinoma
Online Access:https://doi.org/10.1002/ctm2.1267

Internet

https://doi.org/10.1002/ctm2.1267

Similar Items